Serum Amyloid P Immunoreactivity in Cortical Tangles, Plaques and Vessels in Alzheimer’s Disease: Implications for Dysfunction of the Blood-Brain Barrier?

  • Rajesh N. Kalaria
Part of the Advances in Behavioral Biology book series (ABBI, volume 38A)


Amyloid P component (AP) is an α 1-glycoprotein found in almost all types of amyloid deposits, representing 10–20% of the weight of the amyloid fibrilsl. AP is a normal constituent of serum (SAP) synthesized by the liver, the only tissue that appears to exhibit its mRNA2. Investigators have previously attempted to demonstrate the immunocytochemical localization of SAP in brain amyloid deposits of subjects with Alzheimer’s disease (AD). In earlier studies3–5, positive SAP antigenicity was evident only in cerebral vessels of AD subjects and those of hereditary cerebral hemorrhage with amyloidosis of the Icelandic type3,6. More recently such immunoreactivity has been demonstrated in senile plaques of AD5,6, as well as cerebral vessels, and in other related disorders exhibiting cerebral amyloid angiopathy6 (CAA). However, with the exception of a recent preliminary report7, SAP immunoreactivity has not been, so far, described in neurofibrillary tangles.


Amyloid Deposit Cerebral Amyloid Angiopathy6 Cerebral Vessel Preimmune Serum Rabbit Preimmune Serum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    G. G. Glenner, Amyloid deposits and amyloidosis. The ßfibrilloses, New Eng. J. Med. 302: 1283–1292 (1980).PubMedCrossRefGoogle Scholar
  2. 2.
    S. Ohnishi, S. Maeda, K. Shimada and T. Arao, Isolation and characterization of the complete complimentary and genomic DNA sequences of human serum amyloid P component, J. Biochem. 100: 849–858 (1986).PubMedGoogle Scholar
  3. 3.
    I. F. Rowe, O. Jensson, P. D. Lewis, J. Candy, G. A. Tennent and M.B. Pepys, Immunohisotchemical demostration of amyloid P component in cerebrovascular amyloidosis, Neuropathol. Appl. Neurobiol. 10: 53–61 (1984).PubMedCrossRefGoogle Scholar
  4. 4.
    P. Westermark, T. Shirahama, M. Skinner, A. Brun, R. Cameron and A. S. Cohen, Immunohistochemical evidence for the lack of amyloid P component in some intracerebral amyloids, Lab. Invest. 46: 457–460 (1982).PubMedGoogle Scholar
  5. 5.
    M. Yamada, H. Tsukagoshi, E. Otomo and M. Hayakawa, Cerebral amyloid angiopathy in the aged, J. Neurol. 234: 371–376 (1987).PubMedCrossRefGoogle Scholar
  6. 6.
    F. Coria, E. Castano, F. Prelli, M. Larrondo-Lillo, S. van Duinen, M. L. Shelanski and B. O. Frangione, Isolation and chracterization of amyloid P component from Alzheimer’s disease and other types of cerebral amyloidosis, Lab. Invest. 58: 454–458 (1988).PubMedGoogle Scholar
  7. 7.
    A. B. Schiebel, E. Pommier and T. Duong, Immunodetection of human serum amyloid P component in Alzheimer’s disease, Soc. Neurosci. Abstr. 13: 1152 (1987).Google Scholar
  8. 8.
    I. Alafuzoff, R. Adolfsson, I. Grundke-Iqbal and B. Winblad, Blood-brain barrier in Alzheimer dementia and in non-demneted elderly, Acta Neuropathol. 73: 160–166 (1987).PubMedCrossRefGoogle Scholar
  9. 11.
    J. A. Hardy, D.M.A. Mann, P. Wester and B. Winblad, An integrative hypothesis concerning the pathogensis and progression of Alzheimer’s disease, Neurobiol. Aging 7: 489–502 (1986).PubMedCrossRefGoogle Scholar
  10. 13.
    J. M. Rozemuller, P. Eikelenboom, W. Kamphorst and F.C. Stam, Lack of evidence for dysfunction of the blood-brain barrier in Alzheimer’s disease: an immunohisto-chemical study, Neurobiol. Aging 9: 383–391 (1988).PubMedCrossRefGoogle Scholar
  11. 14.
    R. N. Kalaria and S.I. Harik, Reduced glucose transporter at the blood-brain barrier and in the cerebral cortex in Alzheimer’s disease, J. Neurochem. 53: 1083–1088 (1989).PubMedCrossRefGoogle Scholar
  12. 15.
    R. N. Kalaria and S.I. Harik, Increased α2- and ß2adrenergic receptors in cerebral microvessels in Alzheimer disease, Neurosci. Lett. (in press) (1989).Google Scholar
  13. 16.
    P.L. McGeer, S. Itagaki and E. G. McGeer, Expression of the histocompability glycoprotein HLA-DR in neuro-logical disease, Acta Neuropathol. 76: 550–557 (1988).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Rajesh N. Kalaria
    • 1
  1. 1.Department of Neurology and Ctr. for NeurosciencesCase Western Reserve University School of MedicineClevelandUSA

Personalised recommendations